Canaccord Genuity Group Reiterates Buy Rating for Prestige Consumer Healthcare (NYSE:PBH)

Canaccord Genuity Group reissued their buy rating on shares of Prestige Consumer Healthcare (NYSE:PBH - Free Report) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $80.00 target price on the stock.

PBH has been the subject of several other research reports. DA Davidson reaffirmed a neutral rating and issued a $65.00 target price on shares of Prestige Consumer Healthcare in a research report on Thursday, May 16th. StockNews.com downgraded Prestige Consumer Healthcare from a strong-buy rating to a buy rating in a report on Tuesday. Finally, TheStreet raised shares of Prestige Consumer Healthcare from a c+ rating to a b- rating in a research report on Monday, February 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of Moderate Buy and a consensus target price of $91.25.

Prestige Consumer Healthcare Price Performance

Shares of PBH traded up $0.35 during trading hours on Tuesday, hitting $65.05. 304,878 shares of the company were exchanged, compared to its average volume of 246,006. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 2.02. The company has a market capitalization of $3.25 billion, a PE ratio of 15.60, a PEG ratio of 1.83 and a beta of 0.53. The firm has a fifty day simple moving average of $70.49 and a 200-day simple moving average of $65.35. Prestige Consumer Healthcare has a one year low of $55.96 and a one year high of $75.31.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported $1.02 earnings per share for the quarter, missing analysts' consensus estimates of $1.14 by ($0.12). The company had revenue of $277.00 million during the quarter, compared to analysts' expectations of $287.42 million. Prestige Consumer Healthcare had a return on equity of 13.48% and a net margin of 18.60%. The company's revenue for the quarter was down 3.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.07 EPS. As a group, sell-side analysts predict that Prestige Consumer Healthcare will post 4.41 earnings per share for the current year.

Institutional Trading of Prestige Consumer Healthcare

Several large investors have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas lifted its holdings in Prestige Consumer Healthcare by 4.5% in the 3rd quarter. Teacher Retirement System of Texas now owns 14,082 shares of the company's stock worth $805,000 after purchasing an additional 602 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Prestige Consumer Healthcare in the 3rd quarter valued at $1,053,000. Illinois Municipal Retirement Fund bought a new position in Prestige Consumer Healthcare in the 3rd quarter worth $1,608,000. Seizert Capital Partners LLC raised its holdings in Prestige Consumer Healthcare by 3.1% in the 3rd quarter. Seizert Capital Partners LLC now owns 51,008 shares of the company's stock worth $2,917,000 after acquiring an additional 1,513 shares during the period. Finally, Swiss National Bank lifted its position in Prestige Consumer Healthcare by 0.6% during the 3rd quarter. Swiss National Bank now owns 108,800 shares of the company's stock worth $6,222,000 after acquiring an additional 700 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.